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A B S T R A C T
Purpose: The goal of this retrospective study is to review the causes of infantile spasms and to correlate
aetiology with outcome.
Methods: All children diagnosed with infantile spasms between 1990 and 2003 at our institution were
included. Charts were reviewed for the presence or absence of a deﬁned aetiology/association, response
to treatment, long-term epileptic and cognitive outcome.
Results: 80 out of 95 children are included in this review. 50 children (63%) had symptomatic spasmswith
disorders of cortical development being the most frequent cause followed by neonatal injury and
tuberous sclerosis. Symptomatic children with developmental brain lesions responded at a rate of 54% to
vigabatrin versus 62% for ACTH/prednisone, while other symptomatic aetiologies 83% responded to
vigabatrin versus 63% for ACTH/prednisone. Cryptogenic spasms responded at a similar rate to both
drugs. Other than children with cryptogenic spasms, very few went on to develop normally. Our results
are however biased by on average more than 30 days of delay to diagnosis. None of our children
developed Lennox-Gastaut syndrome but a number developed severe epilepsy with multifocal spikes.
Discussion: The aetiology and prognosis of infantile spasms is evolving. To improve outcome, we need to
reduce the delay to diagnosis and develop prospective double-blind randomized clinical trials looking at
not only the epileptic outcome but also cognitive outcome of these children.
 2008 Published by Elsevier Ltd on behalf of British Epilepsy Association.
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Infantile spasms, as part or not of West syndrome,1 have been
the subject of numerous reviews throughout the years.2 While
pathophysiological mechanisms remain poorly understood2–5 and
the drug treatment options limited to a few anticonvulsants, much
light has been thrown onto causes or associations mainly due to
the progress in diagnostic means and to a lesser degree, to
epidemiological data.6 Because of the relatively rare incidence of
this condition of 1 per 2000–6000 live births,7,8 the diverse
classiﬁcations9 and themultiple treatment strategies used over the
years as well as the small number of prospective studies with long-
term follow-up, controversy regarding the optimal treatment and
long-term prognosis of the condition remains.10 The goal of this* Corresponding author at: Sainte-Justine Hospital, Neurology Division, Room
5421, 3175 Ste-Catherine Road, Montreal, QC, Canada H3T 1C5.
Tel.: +1 514 345 4931X5394; fax: +1 514 345 4787.
E-mail address: lionel.carmant@umontreal.ca (L. Carmant).
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doi:10.1016/j.seizure.2008.09.006retrospective study is to try to describe the different aetiologies of
infantile spasms encountered in our clinical practice and to
compare the efﬁcacy of therapeutic modalities based on aetiology
as well as to provide prognostic information on epileptic and
cognitive outcome as the basis for future prospective studies
looking at improving the outcome of this catastrophic form of
epilepsy.
2. Patients and methods
We reviewed the medical records of all the children with a
diagnosis of infantile spasms or West syndrome evaluated at
Sainte-Justine Hospital between January 1990 and August 2003.
We included all children seen either in hospital or in the outpatient
clinic. The presence of hypsarrhythmia was not mandatory
therefore any epileptic interictal pattern on EEG was admissible.
This allowed us to measure the impact of hypsarrhythmia on
outcome. However, we only included children whose EEGs were
obtained at the time of clinical diagnosis andwhowere followed atEpilepsy Association.
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phalographer reviewed all the EEGs (L.C.).
Infantile spasms were classiﬁed into two groups, symptomatic
and cryptogenic according to the ILAE classiﬁcation of the
epilepsies.11Patientswithadeﬁnitecause/associationwere included
in the symptomatic group. Children with cryptogenic IS were
diagnosed when medical history, clinical evaluation and investiga-
tionsdidnot lead toanaetiologicaldiagnosis. Intheabsenceof formal
developmental evaluations, we did not classify as idiopathic IS.19
Investigation including the Wood’s lamp skin assessment, neuroi-
maging (MRIorCT)andbasicmetabolic studies (aminoacids, organic
acids, lactate, pyruvate and ammonia levels) were available in all
patients. Further work-up (video-EEG, genetics, heart ultrasound/
MRI, cerebralPETand/orSPECT,musclebiopsy,othermetabolic tests,
etc. . .) was done as needed on an individual basis.
Sex, age at onset of spasms, family history of epilepsy (1st and
2nd degree relatives), signiﬁcant pre-/peri/post-natal insults, lead-
time to clinical diagnosis (deﬁned as the time from the initial
observation of spasms to the clinical diagnosis), and the follow-up
period (from clinical diagnosis to last neurology visit) were
recorded. The existence of pre-, post- and concomitant seizures
was also recorded. The response to the initial treatment, as well as
the response time (deﬁned as the period between treatment
initiation and the cessation of spasms) was included in the
database. The response to treatment was classiﬁed as follows:
complete (no relapse observed after last spasm for the entire
follow-up period), transient (relapse of spasms after at least a 7-
day spasm free period) and no response. For purpose of analysis,
we recorded both initial response to appropriate therapy and long-
term clinical response. The patients who relapsed were considered
as non-responders only if an increase or a change of medication
was not successful in controlling their spasms. They were
considered long-term responders if an increment of the initial
medication or a second treatment course controlled IS on a long-
term. The length of treatment was also calculated for all patients.
Finally, we recorded the developmental outcome at last follow-up
visit (cognitive and motor), the presence of autistic features and of
attention deﬁcit disorder with or without hyperactivity based on
the neurologist’s assessment.Table 1
Clinical response to treatment and outcome based on aetiology.
Aetiology Number of
children
Complete
response GVG
Post-relapse
control GVG
Complete r
steroids
Cortical dysplasia 7 1/5 1/3
Tuberous sclerosis 7 5/5 1/1
Cerebral atrophy 7 0/4 2/3
Trisomy 21 4 1/2 0/1 2/3
Polymalformative 2 0/1 0/1
PVNH 1 1/1
Microcephaly 1
Lissencephaly 1 1/1
Pachygyria 1 0/1
Holoprosencephaly 1 0/1
Polymicrogyria 1 0/1
Williams 1 1/1
Aicardi 1 1/1
Agenesis of c.c. 1 1/1
Microdysgenesis 1 0/1 0/1
Post-infection 4 1/1 1/2
Diffuse HIE 3 0/1 1/2
Stroke 3 1/3
PVL 1 1/1
Lactic acidosis 1 1/1
Hypoglycemia 1 0/1 1/1
Cryptogenic 30 14/17 11/13
GVG: vigabatrin; PVNH: periventricular nodular heterotopias; c.c.: corpus callosum; PVL:
acid; HIE: Hypoxic-Ischemic Encephalopathy.3. Results
3.1. Epidemiology
A total of 80 children were included in the study, 34 females
and 46 males. 15 more were excluded due to missing data. These
patients were not followed at Sainte-Justine or were seen at
Sainte-Justine for a second opinion usually to obtain a surgical
evaluation. 50 out of the 80 remaining children had symptomatic
spasms (62.5%) and 30 cryptogenic (37.5%). We encountered a
vast number of aetiologies/associations in the symptomatic
group. We separated them into two large categories. The ﬁrst
included 37 children with developmental lesions and the second
13 children acquired lesions or associations (Table 1). Patients
who relapsed on treatment or after tapering off are counted in the
post-relapse control column only. In the other drug group, we
included either patients who did not try vigabatrin, steroids or
topiramate at any time or those who tried one of these drugs but
responded only when another non-conventional treatment was
added.
We had sufﬁcient information to calculate the mean lead-
time to diagnosis in 69 patients. The mean delay was 36.8  69.3
days. No statistically signiﬁcant difference among the symptomatic
versus cryptogenic groups was observed. The mean age at
diagnosis was overall 7.21  4.7 months, again not different
amongst the groups.
3.2. Genetics
We did not ﬁnd families with multiple children affected by
infantile spasms. However, a twin with cryptogenic infantile
spasms shared with his identical twin a hypsarrhythmic EEG
pattern. Both were treated and showed a complete response to
vigabatrin. Although the sibling actually never had clinical
evidence of spasms, the EEG pattern responded to therapy and
his developmental outcome is normal, like his twin.
However, 15 out of 30 children (50%) with cryptogenic spasms
had a positive family history of epilepsy. Among these 15 familial
cases, the vastmajorityweremales (n = 12; 80%) and 4 of themhadesponse Post-relapse
control steroids
Response
to TPM
Response
to other AED
Normal cognitive
development
0/1 0/1 0/7
0/1 0/7
1/1 0/1 1/7
0/4
0/1
0/1
0/1 0/1
0/1
1/1 (cnz) 0/1
1/1 (cnz) 0/1
0/1 0/1
0/1
0/1
0/1
0/1
0/2 0/4
0/1 0/3
1/1 0/3
0/1
0/1
0/1
0/2 0/2 1 (vpa) 16/30
periventricular leukomalacia; AED: anticonvulsant; cnz: Clonazepam; vpa: Valproic
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15 out of 49 (30.6%) symptomatic patients had a positive family
history, including the patient with Aicardi syndrome, and 4/11
children with various forms of cortical dysplasias.
3.3. Seizure types and EEG ﬁndings
18 children experienced seizures prior to developing infantile
spasms. 15 out of 18 (83.3%) were diagnosed with a deﬁned
aetiology. Neonatal seizures were observed in 3 children while
partial or secondarily generalized seizures were seen in 12.
32 out of 50 (64%) patients in the symptomatic group had
hypsarrhythmia on their EEG at diagnosis. The most consistent
association was with trisomy 21, in which 3 out of 4 children
presented with hypsarrhythmia at diagnosis (75%). All had a
favourable seizure outcome, a ﬁnding, which is in keeping with
the literature.12–14 In contrast, 7 children had tuberous sclerosis
but only 3/7 had hypsarrhythmia, while the others showed
multifocal epileptiform discharges. All children responded to
treatment, but 3 had recurrent spasms, 1 with hypsarrhythmia
treated with ACTH and 2 with multifocal EEG changes 1 treated
with vigabatrin and the other with valproic acid and vitamin B6.
2 children with TS had persistent partial seizures post-spasms,
both with initially multifocal EEGs. Post-treatment EEG
remained abnormal at 1 month more often in the hypsarrhyth-
mic group compared to the non-hypsarrhythmic group. In the
symptomatic group, 6/32 children with hypsarrhythmia had a
repeat EEG that became normal immediately after treatment but
3 out of these 6 eventually showed some epileptiform EEG
activity. Most children showed post-spasms either a multifocal
EEG pattern (n = 21) or focal discharges (n = 20). 5 children
developed generalized epileptic discharges and the rest had
an abnormal background without epileptic activity.13 Finally,
hypsarrhythmia persisted in 3 out of 32 symptomatic patients
(9%) 1-month post-treatment none of which responded clini-
cally. However, none went on to fulﬁll the diagnostic criteria for
Lennox-Gastaut syndrome.15,16
In the cryptogenic group, 23 of 30 patients had pre-treatment
hypsarrhythmia, in none did it persist after treatment. In 16, the
EEG normalized at the ﬁrst follow-up control with 13 going on to
develop normally.
3.4. Incidence of behavioural disorders
Althoughmost childrenwere developmentally delayed, autistic
features appeared after the onset of spasms in 1 child with
tuberous sclerosis (1/7), in 2 with cortical dysplasia (2/7) and in 2
with cryptogenic spasms (1 had family history of schizophrenia).
ADHD developed in 4 out of 50 symptomatic, 6 out of 30
cryptogenic spasms.
3.5. Developmental outcome
Of all symptomatic patients, only 1 child with a diagnosis of
cerebral atrophy showed a normal development at the last follow-
up visit (Table 1). None of the children with tuberous sclerosis had
a completely normal development despite 5/5 responding to
vigabatrin and 1/1 to ACTH. The only child with persistent spasms
only received non-conventional treatment. They all developed
language delay and 5/7 also had motor delay.
Half of the children with cryptogenic infantile spasms showed
no developmental delay at last follow-up (Table 1). All showed an
early recuperation of development and arrest of spasms with
treatment initiation with either ACTH (n = 11) or vigabatrin
(n = 14).3.6. Treatment outcome
Vigabatrin was given to 50 patients, 46 as ﬁrst line therapy. The
total recorded mean duration of treatment was 21  18.9 months
with aminimumof 0.2months and amaximumof 76months,median
14 months. ACTH and/or prednisone were given to 39 patients, 34 as
ﬁrst line therapy. The total recorded mean duration of treatment was
41.62  60.9 days, minimum 10 and maximum 365 days (predni-
sone), median 28 days.
In children with cryptogenic spasms, there was no difference
between vigabatrin and ACTH for seizure control (Table 1). No
statistically signiﬁcant difference was found among vigabatrin’s
and ACTH’s response times when these were given as a ﬁrst choice
treatment in patients who responded completely nor was there
any difference in the risk of relapse.
We analyzed outcome based on aetiology for the symptomatic
cases (Table 1). Of the 23 children with developmental brain
lesions treated with vigabatrin, 11 responded with complete
cessation or where controlled after increasing the dosage when
they relapsed. 6 children relapsed on vigabatrin, including 4 with
diffuse atrophywho did not regain spasm control. For steroids, 7 of
15 responded including 1 who relapsed after an initial response.
Only 1 child with focal cortical dysplasia relapsed and he was also
never able to regain spasm control.
For the acquired lesions associatedwith IS, 4 out of 8 responded
to vigabatrin with no relapse, while 4 out of 6 responded to
steroids, including 1 who relapsed on treatment.
In cryptogenic IS, both drugs were highly effective with 14 out
of 17 (82.3%) responding to vigabatrin and 11 of 13 to steroids
(84%).
Topiramate was used in 6 patients with refractory spasms and
was effective in 1 child with diffuse cerebral atrophy. A number of
other anticonvulsants were tried in this population, cessation
of spasms was reported in 2 children after the introduction of
clonazepam (2/12) and in 1 child after valproic acid (1/18). 1 child
out of 2 responded to the introduction of the ketogenic diet. Other
failed treatments included vitamin B6, nitrazepam and clobazam.
4. Discussion
4.1. The changing epidemiology of infantile spasms
The incidence of IS is estimated to be 1 per 2000–6000 live
births7,8 with a peak age of onset at 6months. Each yearworldwide
2 million new cases are diagnosed.6,17 Up to 75% of children have
an underlying disorder. The principal aetiologies of spasms are
hypoxic-ischemic injury, neurocutaneous syndromes, cerebral
dysgenesis, inborn errors of metabolism, intrauterine or post-
natal infections, and intracranial haemorrhage.18 Due to better
imaging techniques, mainly MRI, a number of patients, formerly
classiﬁed as cryptogenic can now be included in the symptomatic
group. In our population, we identiﬁed in 63% of patients with
new-onset infantile spasms an underlying aetiology. This is
slightly less than in other series probably due to the fact that
only well-documented diagnoses or associations were included.
For example, for hypoxic-ischemic injury to be included as a
diagnosis required clinical as well as imaging evidence of injury in
the ﬁrst 24 h of life.20 However, we did include in our group
children with cerebral atrophy, which is a non-speciﬁc diagnosis.
In our cohort, the latter was one of the most frequent aetiologies
with tuberous sclerosis and focal cortical dysplasia. Indeed,
malformations of brain development disorders, including atrophy
and various syndromes, were the most common aetiologies
with 37 out of 50 children with symptomatic cases. This is
overwhelmingly more than perinatal injury (6 patients in our
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supports that it is therefore imperative that a complete diagnostic
work-up should be performed in children with IS even those
bearing a diagnosis of perinatal injury. For instance, the child in
this cohort with the Aicardi syndrome was carrying a hypoxic-
ischemic injury diagnosis to explain her early developmental delay
up to the onset of spasms, when an ophthalmology evaluation was
performed, and the proper diagnosis made.
Signiﬁcant progress has been made towards the identiﬁcation
of speciﬁc genes causing infantile spasms. Tuberous sclerosis was
the ﬁrst genetic disorder associated with IS. More recently,
mutations in at least four genes predisposing to cortical dysplasias
associated with IS have been identiﬁed, including: (1) LIS1, causing
mainly lissencephaly, but also subcortical band heterotopia;25 (2)
DCX, causing lissencephaly in males, and subcortical band
heterotopia in females;26 (3) ARX, causing X-linked lissencephaly,
corpus callosum agenesis and ambiguous genitalia;27,28 and (4)
FLNA causing periventricular nodular heterotopia.29 In contrast to
symptomatic IS, little is known on the genetics of cryptogenic and
IS. The high incidence of a positive family history in the children
with cryptogenic spasms in our cohort (50%) strongly supports an
underlying genetic susceptibility for this subset of IS. Finally,
disruption of CDKL5 gene was found in 1 girl with cryptogenic IS.30
Mutations in CDKL5 have been associated with atypical Rett
syndrome, including IS, mental retardation, stereotypic hand
movements, and episodes of hyperventilation.31,32 Further studies
are required in our population to better understand the role of
genetics in IS.
4.2. Outcome of infantile spasms
Our group and others have shown that certain aetiologies of IS
appear to have a relatively better outcome. These include
conditions such as tuberous sclerosis, Aicardi syndrome and
trisomy 21.22,23 In this retrospective study, we were not able to
demonstrate superiority of one treatment over the other in any
speciﬁc syndrome either in the short- or long-term. These results
differ from the UKISS study.35 In that prospective study, ACTH
seemed to be superior to VGB in the short-term, with similar
response on the long-term for both medications. ACTH was also
superior to VGB in cryptogenic patients, a result we cannot conﬁrm
with our study As early control of spasms could play a role in
improving cognitive outcome the authors supported ACTH as the
initial treatment of IS. Obtaining prospective data using develop-
mental scales to support this conclusion would be a major
advancement in improving the treatment of IS. If we believe the
cognitive impact of IS is due to the constant epileptic discharges, in
our cohort the subgroup with cryptogenic spasms had a similar
lead-time to diagnosis than the symptomatic group. In our
population, the lead-time to clinical diagnosis was remarkably
long. The mean delay to diagnosis was more than a month in both
groups. And some of the children in the cryptogenic group still had
a favourable outcome despite delaying treatment by more than 90
days. This suggest that some children could have a superior
potential and some remain within normal limits despite the IS and
hypsarrhythmia. Whether or not IS had an impact on the
development of these children would require prospective devel-
opmental evaluations.
The great variability in the delay to diagnosis could be
explained by the atypical symptomatology of infantile spasms,
which is different than those of other seizure types. But, we believe
that this delay reﬂects the limited awareness of primary care
physicians and families to IS as a consequence or complication of
neurodevelopmental/early life disorders. With the beneﬁts
described in treating IS as early as possible in certain conditionslike tuberous sclerosis and Aicardi syndrome,22,23 our data might
suggest that parents and physicians treating children should be
informed of IS as a possible complication (not only complex partial
or generalized seizures) and even that an EEG could be part of the
routine evaluation of developmentally delayed children between 3
and 10months of age. Perhaps – in conjunctionwith epidemiologic
studies concerning the incidence of infantile spasms in particular
diseases – it might be useful to screen speciﬁc groups of children
with EEG, in order to detect hypsarrhythmia (or multifocal
discharges) in an early stage.5,6 This is re-enforced by the
observation of an improved outcome in children with cryptogenic
spasms treated within a month of diagnosis.24
More than half (61%) of children in our cohort remained
epileptic at the end of the spasms. Of the 31 who did not develop
epilepsy following IS, 12 were symptomatic with 1 trisomy 21, 3
tuberous sclerosis, 4 cerebral atrophy, 3 post-infectious, 1 with
cortical developmental disorder; 19 were cryptogenic. Another
important observation is that despite a follow-up of more than 4
years, no case fulﬁlled the criteria for Lennox-Gastaut syndrome.
Indeed, while it is said that 25% of childrenwith IS go on to develop
Lennox-Gastaut syndrome, our children with multiple seizure
types, whether or not tonic seizures were observed, did not show
the typical slow spike and wave pattern of Lennox-Gastaut
syndrome. These children evolved more often with the multifocal
epileptic pattern originally described by Markand, Blume and
Ohtahara and recently revisited.33 Whether this improves long-
term outcome remains to be demonstrated.
5. Conclusion
Our results suggest that despite the fact that infantile spasms
are a severe neurological condition, diagnosis is too often delayed.
Education is therefore required for parents and health care
providers involved in the care of children with developmental
delay to try and limit this as early treatment might improve
outcome.24 The optimal treatment strategy remains unknown, but
in our population the two major available drugs (vigabatrin and
ACTH) lead to a similar response rate.34
Finally, the cognitive outcomeof childrenwith IS remains poor in
children who regress with the onset of spasms. Recovery was only
observed in children who responded rapidly and completely to
therapy. Yet, a subgroup of children appears to be resistant to the
deleterious effects of spasms.Weneed tobetter study these children
to conﬁrm the lack of impact of spasms on their development
through repeated developmental evaluations and to assess possible
genetically inherited neuroprotective mechanisms.
Well-structured, prospective trials will be needed in order to
throw some light on the efﬁcacy of therapy in speciﬁc groups, their
effect on patients’ cognitive outcome, as well as the evolution of
this disorder towards other types of epileptic syndromes.
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